MHSC

South Africa Mining Fiscal Landscape Regulations Report 2023: Sustainability, Governing Bodies, Regulations, Licensing Fees, Taxes, Royalties - ResearchAndMarkets.com

Retrieved on: 
Martedì, Febbraio 20, 2024
Professional Services, Public Policy, Government, Mining, Minerals, Environment, Sustainability, Natural Resources, Finance, Doe, Copper, Nickel, Coal, NNR, Mineral, DMR, National Nuclear Regulator, Gold, PGM, Policy, Primary energy, Mineral Resources Limited, MHSC, Diamond, Manganese, Uranium mining

The "South Africa Mining Fiscal Landscape Regulations Governance and Sustainability (2023)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "South Africa Mining Fiscal Landscape Regulations Governance and Sustainability (2023)" report has been added to ResearchAndMarkets.com's offering.
  • The report provides a comprehensive coverage on South Africa's mining fiscal regime.
  • The Department of Mineral Resources and Energy (previously, the Department of Mineral Resources (DMR)) is the primary organization that regulates the country's mining industry.
  • It formulates mining policy pertaining to exploration, development, utilization and processing by the country's mining industry.

Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis

Retrieved on: 
Venerdì, Gennaio 6, 2023
MHSC, Clinical trial, Fibrosis, Drug development, NASH, Inflammation, Cirrhosis, Table, Doctor's visit, Risk, Elastography, Disease, University of Oxford, Patient, Fatty liver disease, Marie Cassidy, 0,1-simple lattice, University, FDA, Therapy, NAS, Conference, University of California, San Diego, Steatohepatitis, Steatosis, Principal, Liver, Biopsy, Medical imaging, Pharmaceutical industry, Madrigal, NAFLD

The new MAESTRO-NASH data are being presented at the NASH-TAG Conference, taking place from January 5-7, 2023 in Park City, Utah.

Key Points: 
  • The new MAESTRO-NASH data are being presented at the NASH-TAG Conference, taking place from January 5-7, 2023 in Park City, Utah.
  • An MRI-PDFF conducted during screening confirmed that patients had NAFLD prior to obtaining a liver biopsy.
  • Each pathologist's scores showed a similar statistically significant magnitude of response at both doses for both liver biopsy endpoints.
  • The consensus read by the two central pathologists reinforced the positive results observed in the primary analysis (Tables 1-2).

89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology

Retrieved on: 
Lunedì, Dicembre 12, 2022
Liver, Steatosis, Health, Inflammation, SAN, Lipid metabolism, Cardiovascular disease, Prevalence, The Lancet, Disclosure, Hepatology, FDA, Hepatocellular carcinoma, Safety, Liver transplantation, FGF21, The O.C., Half-life, Safe harbor, Liver injury, Trial of the century, Risk, MHSC, Conditional sentence, Fibrosis, Lipid, Obesity, University of California, San Diego, Fatty liver disease, Type 2 diabetes, Hypertriglyceridemia, University, COVID-19, Cirrhosis, Patient, Diabetes, NAFLD, Dietary supplement, Pharmaceutical industry

SAN FRANCISCO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that data from cohorts 1-6 in the the Phase 1b/2a proof-of-concept study evaluating pegozafermin for the treatment of nonalcoholic steatohepatitis (NASH) was published online in The Lancet Gastroenterology & Hepatology. Study results showed statistically significant absolute reductions in hepatic fat fraction at week 13 with pegozafermin administered every week or every two weeks compared to placebo. Up to 88% of patients had at least a 30% reduction in hepatic fat fraction, which has been shown to correlate with reduced fibrosis progression.1,2 Furthermore, improvements in liver transaminases (measures of liver injury), measures of fibrosis and lipids were observed with pegozafermin compared to placebo. In this study, pegozafermin was well tolerated with no treatment-related serious adverse events observed.

Key Points: 
  • Study results showed statistically significant absolute reductions in hepatic fat fraction at week 13 with pegozafermin administered every week or every two weeks compared to placebo.
  • In this study, pegozafermin was well tolerated with no treatment-related serious adverse events observed.
  • The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).
  • 89bio claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

MTTI Obtains FDA Allowance of Investigational New Drug (IND) for Hürthle Cell Thyroid Cancer

Retrieved on: 
Giovedì, Dicembre 8, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Serum albumin, NIH, National Institute of Diabetes and Digestive and Kidney Diseases, Standard of care, Thyroid, Investigational New Drug, Kidney, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Patient, Cancer, SSTR2, Degenerative disease, MHSC, Digestive, FDA, Glioblastoma, Efficacy, Risk, IRB, GBM, Health, Institutional review board, Neoplasm, Pharmaceutical industry, MD, Safety

Once approved by IRB, it will enable a Phase I/II clinical study of the Safety, Dosimetry and Efficacy of EBTATE in adult patients with metastatic, radioactive iodine non-responsive Hrthle cell thyroid cancer.

Key Points: 
  • Once approved by IRB, it will enable a Phase I/II clinical study of the Safety, Dosimetry and Efficacy of EBTATE in adult patients with metastatic, radioactive iodine non-responsive Hrthle cell thyroid cancer.
  • EBTATE is a new generation of peptide receptor radiotherapeutic drug that has demonstrated potential clinical superiority over standard of care.
  • Dr. Chris Pak, President & CEO of MTTI commented: The clearance of our IND is an important milestone for MTTI.
  • Having solidified our clinical trial preparedness and manufacturing readiness, we are well-positioned to advance EBTATE to target Hrthle cell thyroid cancer.

Heron Therapeutics Announces U.S. FDA Approval of APONVIE™ (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV)

Retrieved on: 
Venerdì, Settembre 16, 2022
Headache, Dizziness, Condom, Bachelor of Medicine, Bachelor of Surgery, Cochrane, Milk, FRCA, IV, Master of Science, COVID-19, Pain, Heron, Risk, Brain, FDA, Food, Ondansetron, Hormone, Vomiting, U.S. Securities and Exchange Commission, Division, Company, Intrauterine device, News, Private Securities Litigation Reform Act, Achievement, Pharming, Therapy, Forward-looking statement, Patient satisfaction, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Pregnancy, Physician, Duke University Hospital, Standard of care, Antiemetic, Investor relations, Media, Media contacts database, NASDAQ, PONV, Allergy, Clinician Administered PTSD Scale, SAN, Vitamin, Constipation, Aprepitant, Warfarin, Webcast, CINV, Drug discovery, MHSC, Plasma, Fatigue, Pharmaceutical industry, Birth control, Woman, Anesthesia

SAN DIEGO, Sept. 16, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has approved APONVIE (aprepitant) injectable emulsion, for intravenous use for the prevention of postoperative nausea and vomiting (PONV) in adults.

Key Points: 
  • Treatment with aprepitant resulted in approximately 50% fewer patients vomiting in the first 24 and 48 hours compared to ondansetron.
  • "With the approval of APONVIE our acute care portfolio now addresses the two most common concerns of patients and clinicians after surgery, postoperative pain and postoperative nausea and vomiting.
  • APONVIE (aprepitant) injectable emulsion is a substance P/neurokinin-1 (NK1) receptor antagonist, indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.
  • APONVIE is the same formulation as Heron's approved CINVANTI (aprepitant) injectable emulsion formulation for prevention of chemotherapy-induced nausea and vomiting (CINV).

Charles Huang Foundation Makes Record-Breaking Donation to Methodist Hospital in Arcadia

Retrieved on: 
Martedì, Giugno 28, 2022
Innova, Fellowship of the Royal Colleges of Surgeons, Neurosurgery, Patient, Asian Pacific American Heritage Month, Elective surgery, HSBC, San Francisco Chinese Hospital, Methodist Hospital, Wuhan University, Multimedia, Consulate, History, BNP Paribas, California State Assembly Republican Caucus, Consulate-General of China, Los Angeles, MHSC, Cardiac catheterization, Comprehensive, University of California, Irvine Medical Center, University, University of Strathclyde, ATL, CHF, Hybrid operating room, California State Assembly, Donation, Obstetrics, City, Percussion section, Foundation, AAPI, Family, American College, Electrophysiology, Bed, TMT, State, Hospital, Pharmaceutical industry, Medical device

PASADENA, Calif., June 27, 2022 /PRNewswire/ -- Chinese American entrepreneur Dr. Charles Huang, the founder of Charles Huang Foundation (CHF), announced a $7.5 million donation to Methodist Hospital of Southern California (MHSC) in Arcadia, the largest ever single gift in its 119-year history. This is the second donation made to hospitals by Dr. Huang's private foundation following the record-breaking gift to 123-year-old San Francisco Chinese Hospital early this month.

Key Points: 
  • PASADENA, Calif., June 27, 2022 /PRNewswire/ -- Chinese American entrepreneur Dr. Charles Huang, the founder of Charles Huang Foundation (CHF), announced a $7.5 million donation to Methodist Hospital of Southern California (MHSC) in Arcadia,the largest ever single gift in its 119-year history.
  • "We are so fortunate and pleased with this generous gift from Dr. Huang," said Mike Driebe, president of the Methodist Hospital Foundation.
  • Most recently, Dr. Huang made a major donation to San Francisco's Chinese Hospital and created the Charles Huang Foundation Research Fund at the University of California, Los Angeles.
  • About Methodist Hospital of Southern California:
    Founded in 1903, Methodist Hospital of Southern California is a full-service community hospital with 348 licensed beds.

Medicenna Reports Fiscal Year 2022 Financial Results and Operational Highlights

Retrieved on: 
Mercoledì, Giugno 22, 2022
CD25, Population, IL-2, Society, Insurance, Forward-looking statement, CAB, Clinical Cancer Research, Clinical trial, IND, Calendar, Biskit, D&O, Board of directors, GBM, Conference, GLOBE, Observation, CEO, SUD, Coronavirus Scientific Advisory Board (Turkey), CD122, NASDAQ, News, Brain, DRS, Board, The Lancet, Industry, FDA, Drug development, American Association, GMP, American Association for Cancer Research, Cohort, MDNA, SAB, Patient, Mass flow (life sciences), Toxic leukoencephalopathy, ID, Infrared spectroscopy correlation table, Immunotherapy, Association, NK, MBA, Research, Company, Cancer, Bifunctional, MHSC, Partnership, EMA, Pharmaceutical industry, Online gambling, Medical device, Airline, Vaccine

TORONTO and HOUSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced its financial results and operational highlights for the fiscal year ended March 31, 2022. All dollar amounts are expressed in Canadian currency unless otherwise noted.

Key Points: 
  • TORONTO and HOUSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (Medicenna or the Company) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced its financial results and operational highlights for the fiscal year ended March 31, 2022.
  • Program highlights for the year ended March 31, 2022, along with recent developments include:
    Throughout fiscal year 2022, Medicenna completed activities associated with GMP compliant manufacturing of MDNA11 the Companys selective, long-acting and novel IL-2 super-agonist.
  • In April 2022 Medicenna presented results from two of its novel preclinical assets at American Association for Cancer Research meeting.
  • Throughout fiscal year 2022, Medicennas MDNA55 program was highlighted in both peer-reviewed publications and at medical conferences.

Digestive Disease Week (DDW) May 21-24: The Largest International Gathering of Physicians and Key Opinion Leaders in the field of Gastroenterology

Retrieved on: 
Giovedì, Maggio 19, 2022
Diverticulitis, Physician, MHSC, American Gastroenterological Association, KOL, Doctor of Philosophy, Degenerative disease, DDW, AGA, Radiation, AGAF, Liver transplantation, COVID-19, Research, Digestive system surgery, Gastroenterology, SAN, Lists of people executed in the United States, Gastroparesis, Transplant, University, Non-alcoholic fatty liver disease, Name, SIBO, NAFLD, MAFLD, MD, Impact, Transparency, Medicine, Dentistry

As one of the largest international gatherings of physicians and researchers in the field of gastroenterology, DDW provides a unique opportunity to learn about the latest advances in treatments and therapies for digestive diseases.

Key Points: 
  • As one of the largest international gatherings of physicians and researchers in the field of gastroenterology, DDW provides a unique opportunity to learn about the latest advances in treatments and therapies for digestive diseases.
  • This year's event will feature hundreds of educational sessions, including keynote lectures, symposia, hands-on workshops, and more.
  • Another key opinion leader that will be present at the gathering is Dr. Nicolas Vauthey, a medical doctor who specializes in endocavitary irradiation and radiotherapy.
  • He is considered to be a KOL in these fields, as evidenced by his prominent ranking on the Key Opinion Leaders search engine (keyopinionleaders.com).

BrainStorm Cell Therapeutics Announces First Quarter 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Lunedì, Maggio 16, 2022
Senior, Medical Affairs Bureau, MHSC, ISCT, American Academy, Exo, International Society, Master of Science, ISEV, Drug development, Research, VP, NEW, Hospital, Doctor of Philosophy, Clinical, Company, Webcast, Patient, NASDAQ, ADV, Therapy, Episcopal conference, MPH, Adult, Antal, Neurology, Neurodegeneration, Cerebrospinal fluid, Conference, Conference call, Neuroprotection, Congress, Biomarker, HIV disease progression rates, Proning, Division, Massachusetts General Hospital, Harvard Medical School, Muscular dystrophy, Growth, Development, ALS, Management, Pharmaceutical industry, Medical device, Online gambling, MD

NEW YORK, May 16, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Key Points: 
  • The presentation was delivered by Dr.Kim Thacker, Senior Vice President, Medical Affairs and Clinical Innovation, BrainStorm Cell Therapeutics.
  • Announced upcoming presentations at the ALS Drug Development Summit (May 25, 2022) and the ISEV 2022 Annual Meeting (May 26, 2022).
  • Presented a corporate and Phase 3 ALS clinical overview at the 12thAnnual California ALS Research Summit on January 27, 2022 by Ralph Kern MD MHSc, President and Chief Medical Officer Brainstorm Cell Therapeutics.
  • Net loss per share for the three months ended March 31, 2022, and 2021 was $0.15 and $0.19 respectively.

BrainStorm Announces Presentation of NurOwn® Exosome Preclinical Data at ISCT 2022 San Francisco Meeting

Retrieved on: 
Mercoledì, Maggio 4, 2022
COVID-19, Amyotrophic lateral sclerosis, California Institute for Regenerative Medicine, Immunomodulation, M1, National, Senior, EMA, TGM2, NASDAQ, Multiple sclerosis, European Medicines Agency, Company, Proning, MS, Annual report, Food, Safety, Cell, Regenerative medicine, Poster, CA, Exo, ISCT, Gene, Neurodegeneration, Clinical trial, NTFS, FDA, Brainstorm, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gene expression, Orphan drug, MD, Medical Affairs Bureau, Exosome, MHSC, Phrase, Microsoft, IL10, Research, International Society, CIRM, Nave, Silk, Pharmaceutical industry, Vaccine, ALS

NEW YORK, May 4, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "MSC-NTF derived small extracellular vesicles display superior macrophage immunomodulation compared with vesicles derived from naïve MSCs," at the International Society of  Cell & Gene Therapy ISCT 2022 Meeting, being held from May 4-7, 2022 in San Francisco, CA. The poster will be presented by Dr. Kim Thacker, Senior Vice President, Medical Affairs and Clinical Innovation, BrainStorm Cell Therapeutics.

Key Points: 
  • The poster will be presented by Dr. Kim Thacker, Senior Vice President, Medical Affairs and Clinical Innovation, BrainStorm Cell Therapeutics.
  • Exo MSC-NTF treatment led to statistically significant 6.4 and 3.3-fold reductions in the secretion and transcription (gene expression) of the pro-inflammatory cytokine MCP-1.
  • "These compelling preclinical data provide important insights into Exo MSC-NTF's mechanism of action," said Ralph Kern, MD MHSc, President and Chief Medical Officer of BrainStorm.
  • BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.